Dianna L. DeVore, Ph.D., is a member of the Post-Grant Patent practice group. Dr. DeVore has over 18 years’ experience in intellectual property and transactional law, including providing product protection strategies and coordinating adversarial proceedings in technology areas such as molecular diagnostics, therapeutic monoclonal antibodies, genomics, medical devices and regenerative medicine. Dr. DeVore has represented companies ranging from emerging technology companies to large pharmaceutical companies, and specializes in strategies for USPTO inter partes review proceedings concurrent with complex district court and federal circuit litigations.
From 2010 through June 2014, Dr. DeVore was Vice President of Intellectual Property and Legal Affairs at Ariosa Diagnostics, Inc. a company providing non-invasive prenatal testing services for assessing the risk of various fetal chromosomal aneuploidies. While at Ariosa, Dr. DeVore developed a coordinated intellectual property strategy including post-grant challenges, litigation, and related patent prosecution. Based on her experience in such proceedings, Dr. DeVore has been featured in legal publications including the Recorder, the Daily Journal and the Bloomberg BNA’s Life Sciences Law & Industry Report.
Prior to joining Ariosa Diagnostics, Dr. DeVore was a co-founder of Convergent Law Group, LLP, a silicon valley-based law firm focused on intellectual property, transactional and corporate and prior to that was the Chairman of the Virtual Law Partners Intellectual Property Group. At both firms, Dr. DeVore’s practice focused on providing intellectual property counseling, patent portfolio development, trademark and branding strategies, freedom to operate analysis, negotiating licensing transactions, conducting technology evaluation, establishing corporate and university collaborations, and advising on merger and acquisition transactions.
Dr. DeVore has served as inside counsel for various companies including Complete Genomics, Cambridge Antibody Technology (a wholly-owned subsidiary of AstraZeneca) and Elan Pharmaceuticals. In 2002, Dr. DeVore co-founded the Australian Stem Cell Centre (ASCC) in Melbourne, Australia, the first Australian Biotechnology Centre of Excellence. Dr. DeVore served as the ASCC’s Chief Operating Officer until 2005 and Vice-president, Clinical Cardiac Development from 2005-2006. At the ASCC, Dr. DeVore was responsible for oversight of all operational, corporate, legal and intellectual property activities of the ASCC.